Novartis to Invest US$23 Billion in Florida, USA
Introduction:
Novartis has announced plans to invest US$23 billion to build a radioligand therapy manufacturing facility in Winter Park.
Features:
The development involves the construction of a radioligand therapy manufacturing facility.
Manufacturing operations will support the production of radioligand therapy medicines used in cancer treatment.
Radioligand therapy combines a tumour-targeting molecule with a therapeutic radioisotope to deliver radiation directly to cancer cells.
Production processes will include the preparation of individual radioligand therapy doses.
Manufacturing operations will support time-sensitive production and distribution requirements for radioligand therapy medicines.
The facility will form part of the company’s radioligand therapy manufacturing network in the United States.
The site will support manufacturing and distribution of radioligand therapy medicines across the United States, including treatment centres in the southeastern region.
The facility will operate within the company’s global network of radioligand therapy production sites.
The site will cover approximately 35,000 square feet and expected to become operational by 2029.
Specifications:
| Name | Novartis |
| Type | New Construction |
| Budget | US$23 billion |
| Year | 2029 |
